Andreas Sashegyi

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · The Lancet · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women

Elizabeth Barrett‐Connor, Deborah Grady, Andreas Sashegyi et al. · JAMA · 2002 · 577 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants

Marc E. Lippman, Kathryn A. Krueger, Stephen Eckert et al. · Journal of Clinical Oncology · 2001 · 131 citations

Medicine, Oncology, Pharmacology +17

On the Interpretation of the Hazard Ratio and Communication of Survival Benefit

Andreas Sashegyi, David Ferry · The Oncologist · 2017 · 84 citations · Full text

Public Health, Communication, Health Communication +16

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

Nanette K. Wenger, Elizabeth Barrett‐Connor, Peter Collins et al. · The American Journal of Cardiology · 2002 · 78 citations

Medicine, Cardiology, Pharmacology +8